PRESS RELEASE – Advanced Accelerator Applications receives GMP approval to manufacture

Multi-center Phase III trial of Lutate expected to begin in US and Europe in 2011

December 16, 2010 (Saint Genis Pouilly, France): Advanced Accelerator

Applications (AAA), an emerging international leader in molecular nuclear

medicine, today announced that it has received GMP (Good Manufacturing

Practice) approval for the manufacture of Lutate, a radioactively labelled peptide

that can be used to treat metastatic GastroEnteroPancreatic NeuroEndocrine

Tumors (GEP-NETs).


Leave a Reply